Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Home
»
Target enrollment complete in Phase 1b trial of GT-02287 - Perspectives from Gain Therapeutics
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Related Posts
Target enrollment complete in Phase 1b trial of GT-02287
Parkinson’s News Today
Jul 07, 2025
Target enrollment complete in Phase 1b trial of GT-02287
Related Posts
Post navigation
Previous Post
Gain Therapeutics stock advances as Phase 1b trial enrollment exceeds expectations
Next Post
Gain Therapeutics announces pricing of $7M public offering
Latest Articles
Clear Filters
June 10, 2026
Four emerging technologies reshaping neurology in 2026
https://www.labiotech.eu/in-depth/neurology-technology/
Read More
June 9, 2026
Bial drops pariceract after Phase IIb failure in GBA-associated Parkinson’s
https://european-biotechnology.com/latest-news/bial-drops-pariceract-after-phase-iib-failure-in-gba-associated-parkinsons/
Read More
May 27, 2026
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
https://finance.yahoo.com/sectors/healthcare/articles/gain-therapeutics-expands-compelling-evidence-043446986.html
Read More
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles